Pentasa Alternatives Compared
Pentasa | Entyvio | Zeposia |
|
---|
Pentasa (mesalamine) | Entyvio (vedolizumab) | Zeposia (ozanimod) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Ulcerative Colitis - Active, Ulcerative Colitis - Maintenance, Ulcerative Colitis, Ulcerative Proctitis. Pentasa may also be... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Zeposia is an S1P receptor modulator that may be used to treat relapsing forms of multiple sclerosis or ulcerative colitis in adults. It requires a 7-day titration period and reduces lymphocyte... View more |
Related suggestions Ulcerative Colitis
|
|||||||||||||||||||||||
More about Pentasa (mesalamine) | More about Entyvio (vedolizumab) | More about Zeposia (ozanimod) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Pentasa has an average rating of 7.8 out of 10 from a total of 90 ratings on Drugs.com. 72% of reviewers reported a positive effect, while 9% reported a negative effect. |
Entyvio has an average rating of 6.1 out of 10 from a total of 153 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 29% reported a negative effect. |
Zeposia has an average rating of 8.0 out of 10 from a total of 6 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: Pentasa side effects in more detail. |
See also: Entyvio side effects in more detail. |
See also: Zeposia side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Pentasa prices |
View all Entyvio prices |
View all Zeposia prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Other mesalamine brands include: Apriso, Asacol, Asacol HD, Canasa, Canasa Pac, Delzicol, Lialda, Rowasa, Rowasa Sulfite Free, Zaldyon View more | Other vedolizumab brands include: Entyvio Pen |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
10 hours |
600 hours |
264 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category B
No proven risk in humans
Excluding Asacol And Asacol HD
Category C
Risk cannot be ruled out
Asacol And Asacol HD See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 120 drugs are known to interact with Pentasa:
|
A total of 152 drugs are known to interact with Entyvio:
|
A total of 893 drugs are known to interact with Zeposia:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
May 10, 1993 |
May 20, 2014 |
March 25, 2020 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.